USFDA completes inspection at Ind Swift Laboratories’ API facility in Punjab

16 Mar 2020 Evaluate

United States Food and Drug Administration (USFDA) has completed inspection at Ind-Swift Laboratories’ API manufacturing facility at Derabassi (Punjab), near Chandigarh, India, which was conducted from March 9, 2020 to March 13, 2020. The USFDA has cleared this inspection without any 483 observation.

The Derabassi API manufacturing facility of the company, which has 22 Independent manufacturing blocks, is one of the largest manufacturing facility of Northern India, with annual manufacturing capacity of 695 tonnes per annum.

Ind-Swift Laboratories is engaged in the manufacture of Active Pharmaceutical Ingredients (API). The product range of the company includes Macrolide antibiotics, Cardiovascular, Anti histamine, Anti diabetic, Analgesic, Aromatase inhibtors, Anti depressant,Alcohol absistence, etc.  

Ind-Swift Lab. Share Price

129.90 2.25 (1.76%)
28-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1522.40
Dr. Reddys Lab 6405.75
Cipla 1482.00
Zydus Lifesciences 1074.35
Lupin 1625.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.